Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

43.08 +0.98 (+2.33%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V.

< Previous 1 2 3 4 5 6 Next >
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
From Myriad Genetics, Inc.
Via GlobeNewswire
Strategic Buy Lights Up This Biotech Stock: Time to Invest?
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. 
Via MarketBeat
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Earnings Preview: Qiagen
Via Benzinga
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with KRASG12C-mutated advanced or metastatic colorectal cancer. 
Via Benzinga
Exposures Product Safety
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches
QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launches, and a focus on digital and diagnostic advancements. 
Via Benzinga
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
From Myriad Genetics, Inc.
Via GlobeNewswire
Where Qiagen Stands With Analysts
Via Benzinga
Analyst Expectations for Qiagen's Future
Via Benzinga
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
Exposures US Equities
Preview: Qiagen's Earnings
Via Benzinga
QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024
QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc.... 
Via Benzinga
US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition
U.S. stocks are looking to build on past week’s gains, with the mood remaining cautiously optimistic. The major index futures were modestly higher in early trading. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Analyst Expectations for Qiagen's Future
Via Benzinga
Will Chart Analysts Notice Bad Omen on Qiagen's Chart
Via Benzinga
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing... 
Via Benzinga
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects
QIAGEN N.V. (NYSE: QGEN) disclosed its expansion plan in  
Via Benzinga
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics. 
Via Benzinga
These Companies Helped The German DAX Index Hit Its All-time High
The DAX 40 index surged to its all-time high on Tuesday, continuing the remarkable rally that started on October 23rd. The index, which tracks the 40 biggest companies in Germany, soared to a high of... 
Via Talk Markets
Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends
Qiagen NV's (NASDAQ: QGEN) Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the  
Via Benzinga
Earnings Scheduled For October 30, 2023
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter. 
Via Benzinga
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.